General Medical Devices

Olympus Corp.

Olympus Signs International Distribution Agreement for GORE® VIABIL® Biliary Stents with W. L. Gore & Associates

Olympus Launches VISERA™ S OTV-S500 Imaging Platform

Olympus Launches EU-ME3 Ultrasound Processor

Olympus Launches ScopeLocker Air Endoscope Dryer

Olympus Launches EVIS X1™ Endoscope System

Olympus ESD Receives AMA CPT Code Support

Olympus to Showcase Endoscopic Technologies at DDW

FactSet: Olympus Average Rating is Outperform

Changes in the domestic endoscope market

7733

Olympus Shares Jump Most in Six Years on Job Cuts, Overhaul Plan

marketscreener

Olympus Shares Jump Most in Six Years on Job Cuts, Overhaul Plan

Olympus Corp. (OLYMY) reported a decline in Q2 earnings, with revenue falling 4.2% to ¥454,350 million and operating profit down 34.6% to ¥46,133 million for the six months ending September 30, 2025. The Gastrointestinal Solutions Division saw a 4.8% revenue drop, while the Surgical & Interventional Solutions Division decreased by 2.7%. Profit attributable to owners fell 40.4% to ¥29,187 million. Despite challenges from U.S. tariffs and competition, Olympus is investing in strategic initiatives, including a joint venture for endoluminal robots, and remains optimistic about future performance.

Tip Ranks

Olympus Corp. Reports Decline in Earnings Amid Market Challenges

Nov 7 (Reuters) -* JAPAN’S OLYMPUS TO REDUCE HEADCOUNT BY 2,000 IN GLOBAL OVERHAUL - BLOOMBERG NEWS Source text: Further company coverage: (7733.T)

Reuters

Japan's Olympus To Reduce Headcount By 2,000 In Global Overhaul - Bloomberg News

From October 1, 2025 to October 31, 2025, the company has repurchased 6,864,400 shares, representing 0.61% for ¥12,964.95 million. With this, the company has completed the repurchase of 27,630,600 shares, representing 2.45% for ¥49,999.91 million under the buyback announced on May 13, 2025.

Tranche Update on Olympus Corporation's Equity Buyback Plan announced on May 13, 2025.

Olympus Corp :OLYMPUS CORP - TO RETIRE TREASURY SHARES WORTH 2.16% OF OUTSTANDING STOCK ON NOV 28

Olympus Corp - To Retire Treasury Shares Worth 2.16% Of Outstanding Stock On Nov 28

Olympus Corporation, based in Center Valley, Pennsylvania, disclosed on October 31, 2025, a worldwide medical device corrective action aimed at enhancing understanding for the safe and efficient application of bronchoscopes in conjunction with laser therapy, argon plasma coagulation, or high-frequency procedures. This voluntary initiative is set to impact users globally and aims to ensure proper usage of these devices.

Unusual Whales

Olympus updates labeling for bronchoscopes used with laser therapy worldwide. Clarification for safe usage.

Olympus Corporation has launched the NBI+TXI observation mode for its EVIS X1 endoscopy system, enhancing diagnostic capabilities for gastrointestinal and respiratory lesions. While this innovation aligns with Olympus's growth strategy, its impact on revenue depends on regulatory approvals and market rollout. The company forecasts revenue of ¥1,086.7 billion and earnings of ¥125.4 billion by 2028, with a fair value estimate of ¥1,976. However, challenges in the Chinese market and a recent product recall highlight risks to its growth trajectory.

Simplywall

How NBI+TXI Technology Integration at Olympus (TSE:7733) Has Changed Its Investment Story

Olympus Corporation has launched the THUNDERBEAT(TM) II, a next-generation hybrid energy device for soft tissue management, designed for faster hemostatic dissection and vessel transection in laparoscopic and open surgery. The device will be available in Europe starting October 2025, with a subsequent launch in Japan and a global rollout planned. THUNDERBEAT II features three energy modes, refined probe design, and ergonomic handle, enhancing surgical versatility and minimizing thermal impact on surrounding tissues. This launch reflects Olympus' commitment to advancing surgical technology and improving clinical outcomes.

Japan Corporate News

Olympus Launches New Surgical Energy Device for Hemostatic Cutting and Vessel Sealing

Olympus Corporation of the Americas will showcase its ENT portfolio, including the VISERA™ S OTV-S500 imaging platform, at the ARS and AAO-HNS annual meetings in Indianapolis. The platform features advanced diagnostic capabilities, allowing clinicians to switch between imaging modes for enhanced visualization of ENT diseases. Olympus will also demonstrate single-use devices like the CELERIS™ sinus debrider and the E-SteriScope™ flexible video rhinolaryngoscope, aimed at improving outpatient procedures. The nCare™ 4K medical recorder will also be featured, integrating with hospital information systems for efficient patient management.

prnewswire

12:41 ET
			
			
				Olympus to Highlight Versatile ENT Portfolio of Hybrid Endoscopy and Advanced Imaging at AAO, ARS Annual Meetings

In Center Valley, Pennsylvania on October 8, 2025, Olympus Corporation of the Americas, a multinational medical technology firm dedicated to enhancing people's well-being, will present its extensive Ear, Nose, and Throat (ENT) range. This collection provides a versatile endoscopy solution merging modern technology with traditional methods, demonstrating their commitment to improving healthcare.

Olympus to showcase versatile ENT portfolio at AAO, ARS meetings in 2025, emphasizing hybrid endoscopy and advanced imaging.

An international distribution agreement has been established between Olympus Corporation, a global MedTech firm focused on enhancing people's well-being, and the medical products segment of a company in Hamburg, Germany. This agreement was finalized on October 6, 2025, signifying a collaboration aimed at expanding market reach. Center Valley, Pennsylvania serves as the base for Olympus Corporation, showcasing the company's dedication to innovation and promoting healthier, safer, and more fulfilling lives for individuals worldwide.

Olympus and W. L. Gore & Associates partner, expanding endotherapy portfolio globally. Set to enhance medical products.

Olympus Corporation has entered into an international distribution agreement with W. L. Gore & Associates, allowing Olympus to exclusively distribute the GORE® VIABIL® Biliary Endoprosthesis for endoscopic placement. This partnership aims to enhance Olympus's hepatopancreatobiliary portfolio and expand its presence in the gastrointestinal metal stent market. The GORE® VIABIL® stent offers a unique solution for biliary strictures, featuring a non-foreshortening design and a durable barrier to prevent tumor ingrowth. Olympus plans to begin commercialization in Europe and other regions in the coming months.